MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
-
- Yelena Y Janjigian
- Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
-
- Eric Van Cutsem
- Department of Gastroenterology/Digestive Oncology, University Hospitals Leuven & KU Leuven, Leuven, 3000, Belgium
-
- Kei Muro
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, 464-8681, Japan
-
- Zev Wainberg
- Department of Gastrointestinal Medical Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90404, USA
-
- Salah-Eddin Al-Batran
- Institute of Clinical Cancer Research, Krankenhaus Nordwest, University Cancer Center, Frankfurt, 60488, Germany
-
- Woo Jin Hyung
- Department of Surgery, Yonsei University College of Medicine, Seoul, 03722, South Korea
-
- Daniela Molena
- Esophageal Surgery Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
-
- Michelle Marcovitz
- Statistics, AstraZeneca, Gaithersburg, MD 20878, USA
-
- Dario Ruscica
- Global Clinical Development, AstraZeneca, Cambridge, CB2 8PA, UK
-
- Scott H Robbins
- Global Clinical Development, AstraZeneca, Gaithersburg, MD 20878, USA
-
- Alejandra Negro
- Global Clinical Development, AstraZeneca, Gaithersburg, MD 20878, USA
-
- Josep Tabernero
- Medical Oncology Department, Vall d'Hebron Hospital Campus & Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, 08035, Spain
収録刊行物
-
- Future Oncology
-
Future Oncology 18 (20), 2465-2473, 2022-05-10
Informa UK Limited
